Logo
x

Search

Subscribe Now

Prestige BioPharma

Prestige Biopharma Reports the CHMP’s Positive Opinion of Tuznue (Biosimilar, Herceptin)

Prestige Biopharma Reports the CHMP’s Positive Opinion of Tuznue (Biosimilar, Herceptin)

  • July 29, 2024
Prestige Biopharma Withdraws the MAA for HD201 (biosimilar, trastuzumab) from the EMA

Prestige Biopharma Withdraws the MAA for HD201 (biosimilar, trastuzumab) from the EMA

  • September 16, 2022
Prestige Biopharma Entered into a Binding Agreement with Intas to Commercialize HD204 (biosimilar, bevacizumab) in Multiple Countries

Prestige Biopharma Entered into a Binding Agreement with Intas to Commercialize HD204 (biosimilar, bevacizumab) in Multiple Countr...

  • July 26, 2022
Prestige BioPharma Published Results of HD201 (biosimilar, trastuzumab) for the Treatment of ERBB2+ Breast Cancer in JAMA Oncology

Prestige BioPharma Published Results of HD201 (biosimilar, trastuzumab) for the Treatment of ERBB2+ Breast Cancer in JAMA Oncology

  • March 24, 2022
Prestige BioPharma Publishes the Results of Tuznue (biosimilar, trastuzumab) in the JAMA Oncology

Prestige BioPharma Publishes the Results of Tuznue (biosimilar, trastuzumab) in the JAMA Oncology

  • March 17, 2022
Prestige BioPharma’s Tuznue, a proposed biosimilar to Herceptin Receives EU-GMP Certification for the Treatment of Gastric & Breast Cancer

Prestige BioPharma’s Tuznue, a proposed biosimilar to Herceptin Receives EU-GMP Certification for the Treatment of Gastric & Breas...

  • February 21, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.